SI0863897T1 - 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4- or h3-receptor ligands - Google Patents

5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4- or h3-receptor ligands

Info

Publication number
SI0863897T1
SI0863897T1 SI9630092T SI9630092T SI0863897T1 SI 0863897 T1 SI0863897 T1 SI 0863897T1 SI 9630092 T SI9630092 T SI 9630092T SI 9630092 T SI9630092 T SI 9630092T SI 0863897 T1 SI0863897 T1 SI 0863897T1
Authority
SI
Slovenia
Prior art keywords
oxadiazol
piperidin
phenyl
derivatives
receptor ligands
Prior art date
Application number
SI9630092T
Other languages
English (en)
Slovenian (sl)
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruz Laurence De
Original Assignee
Sanofi - Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Sanofi - Synthelabo filed Critical Sanofi - Synthelabo
Publication of SI0863897T1 publication Critical patent/SI0863897T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI9630092T 1995-11-09 1996-11-05 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4- or h3-receptor ligands SI0863897T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique
EP96937390A EP0863897B1 (fr) 1995-11-09 1996-11-05 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h3
PCT/FR1996/001730 WO1997017345A1 (fr) 1995-11-09 1996-11-05 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h¿3?

Publications (1)

Publication Number Publication Date
SI0863897T1 true SI0863897T1 (en) 1999-10-31

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630092T SI0863897T1 (en) 1995-11-09 1996-11-05 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4- or h3-receptor ligands

Country Status (29)

Country Link
US (1) US5929089A (cs)
EP (1) EP0863897B1 (cs)
JP (1) JP4263240B2 (cs)
CN (1) CN1077891C (cs)
AR (1) AR004708A1 (cs)
AT (1) ATE181328T1 (cs)
AU (1) AU707325B2 (cs)
BG (1) BG63463B1 (cs)
BR (1) BR9611311A (cs)
CA (1) CA2236357C (cs)
CO (1) CO4770968A1 (cs)
CZ (1) CZ287268B6 (cs)
DE (1) DE69602970T2 (cs)
EE (1) EE03487B1 (cs)
ES (1) ES2135934T3 (cs)
GR (1) GR3030823T3 (cs)
HU (1) HUP0001168A3 (cs)
IL (1) IL124364A (cs)
MX (1) MX9803696A (cs)
NO (1) NO309606B1 (cs)
NZ (1) NZ321626A (cs)
PL (1) PL186204B1 (cs)
RU (1) RU2167160C2 (cs)
SI (1) SI0863897T1 (cs)
SK (1) SK282335B6 (cs)
TR (1) TR199800827T2 (cs)
TW (1) TW371303B (cs)
UA (1) UA50748C2 (cs)
WO (1) WO1997017345A1 (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
JP2002504896A (ja) * 1997-05-06 2002-02-12 サノフィ−サンテラボ ５−フェニル−１，３，４−オキサジアゾール−２（３ｈ）−オン誘導体およびそれらの５−ｈｔ４リガンドとしての使用
FR2763068B1 (fr) * 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US6664286B1 (en) 1998-09-18 2003-12-16 Alcon Manufacturing, Ltd. Serotonergic 5ht2 agonists for treating glaucoma
AU5259100A (en) * 1999-04-28 2000-11-10 Respiratorius Ab Medicament
CN1355698A (zh) * 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
WO2002012214A2 (en) 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical Inc. Non-imidazole aryloxyalkylamines as h3 receptor ligands
DE60118754T2 (de) * 2000-08-08 2007-01-11 Ortho-Mcneil Pharmaceutical, Inc. Bicyclische verbindungen als h3 rezeptor liganden
ATE354568T1 (de) 2000-08-08 2007-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
DE60234453D1 (de) 2001-07-02 2009-12-31 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
DE60237528D1 (de) 2001-09-14 2010-10-14 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
JP2005508907A (ja) * 2001-09-14 2005-04-07 ノボ　ノルディスク　アクティーゼルスカブ ヒスタミンｈ３受容体に選択的に結合する置換されたピペリジン
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
JP4563675B2 (ja) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用
AU2002346671B2 (en) 2001-12-14 2005-08-11 Alcon, Inc. Aminoalkyl-benzofuran-5-OL compounds for the treatment of glaucoma
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EA200801608A1 (ru) 2004-06-15 2008-10-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
MX2007015675A (es) * 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
WO2007063012A1 (en) * 2005-12-01 2007-06-07 F. Hoffmann-La Roche Ag Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors
BRPI0711370A2 (pt) 2006-05-29 2011-11-01 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)pi ridazina e seus sais e solvatos e seu uso como antagonista receptor h3 de histamina
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
SG2014003560A (en) * 2011-09-19 2014-11-27 Suven Life Sciences Ltd Heteroaryl compounds as 5-ht4 receptor ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055476A (en) * 1990-08-13 1991-10-08 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
NZ243993A (en) * 1991-08-20 1994-10-26 Smithkline Beecham Plc Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity
US5580885A (en) * 1991-09-12 1996-12-03 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
JPH07503480A (ja) * 1992-02-06 1995-04-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ４拮抗薬としてのベンゾピラン，ベンゾチオピランおよびベンゾフラン誘導体
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
UA50748C2 (uk) 2002-11-15
CO4770968A1 (es) 1999-04-30
NO982092L (no) 1998-06-29
TR199800827T2 (xx) 1999-02-22
DE69602970D1 (de) 1999-07-22
ATE181328T1 (de) 1999-07-15
US5929089A (en) 1999-07-27
CN1202169A (zh) 1998-12-16
NO982092D0 (no) 1998-05-07
CA2236357C (en) 2006-10-17
CZ287268B6 (en) 2000-10-11
EP0863897B1 (fr) 1999-06-16
RU2167160C2 (ru) 2001-05-20
HUP0001168A2 (hu) 2001-04-28
AU7500196A (en) 1997-05-29
MX9803696A (es) 1998-09-30
CN1077891C (zh) 2002-01-16
CA2236357A1 (en) 1997-05-15
PL186204B1 (pl) 2003-11-28
CZ142198A3 (cs) 1998-08-12
TW371303B (en) 1999-10-01
WO1997017345A1 (fr) 1997-05-15
SK59998A3 (en) 1998-11-04
IL124364A0 (en) 1998-12-06
NZ321626A (en) 1998-10-28
BG63463B1 (bg) 2002-02-28
AR004708A1 (es) 1999-03-10
IL124364A (en) 2001-08-08
EP0863897A1 (fr) 1998-09-16
JP4263240B2 (ja) 2009-05-13
GR3030823T3 (en) 1999-11-30
BR9611311A (pt) 1999-06-29
NO309606B1 (no) 2001-02-26
PL326671A1 (en) 1998-10-12
EE9800155A (et) 1998-12-15
BG102412A (en) 1999-08-31
HK1016165A1 (en) 1999-10-29
SK282335B6 (sk) 2002-01-07
EE03487B1 (et) 2001-08-15
AU707325B2 (en) 1999-07-08
ES2135934T3 (es) 1999-11-01
DE69602970T2 (de) 2000-01-20
JP2000500125A (ja) 2000-01-11
HUP0001168A3 (en) 2001-07-30

Similar Documents

Publication Publication Date Title
SI0863897T1 (en) 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4- or h3-receptor ligands
ZA95305B (en) 1,2,4-oxadiazole derivatives
HUP0001098A3 (en) Heterocycle derivatives which inhibit factor xa
HU9601865D0 (en) Antifungal sordaridin derivatives
ZA952431B (en) New piperidine derivatives
ZA953089B (en) Fungicidal azole derivatives
GR3035663T3 (en) Benzisoxazole and indazole derivatives as antipsychotic agents
IL132352A0 (en) 5-Aryl-3-(8-azabicyclo (3.2.2) oct-3yl) -1,3,4-oxadiazol 22 (3h) - one derivatives as 5-ht4 receptor ligands
GB9704376D0 (en) Tetrahydropyridine derivatives as dopamine receptor subtype ligands
ZA95306B (en) 3-aryl-alkenyl-1,2,4-oxadiazole derivatives
ZA972329B (en) Piperidine derivatives
AU4264096A (en) 3,4-dihydro-2,5,7,8-tetramethyl-benzopyran-6-ol derivatives for use as drugs
ZA9510694B (en) 1 3 4-oxadiazine derivatives
AU6506594A (en) 3-phenyl-1,2,5,6-tetrahydropyridine derivatives as sedatives
NZ300041A (en) 2-(2,3,5,6-tetrafluoropyridin-4-yl)-1,2,5-thiazolidin-3-one 1,1-dioxide derivatives
GB9703382D0 (en) Tetrahydropyridine derivatives as dopamine receptor subtype ligands
AU4319797A (en) 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline derivatives or medicinal compositions thereof
AU7658898A (en) 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one derivatives and their use as 5-ht4ligands
ZA969418B (en) 5-Phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol 2(3H)-one derivatives their preparation and their application in therapeutics
ZA9711337B (en) 3-aryl-2-(1-substituted-4-piperidinyl)-1, 1-dioxo-3H-benzo [d]isothiazoles and related compounds.
FR2745574B1 (fr) Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique
DK0863897T3 (da) Derivater af 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-on, som kan anvendes som ligander for 5-HT4- eller H3-recept
FR2741069B1 (fr) Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
GB9404777D0 (en) Thia- & oxadiazole derivatives
SI1019385T1 (en) Aminoaryl oxazolidinone n-oxides

Legal Events

Date Code Title Description
SP73 Change of data on owner

Owner name: SANOFI-AVENTIS; FR

Effective date: 20050204

KO00 Lapse of patent

Effective date: 20140617